{"gene":"PGM1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1984,"finding":"PGM1 and PGM2 isoenzymes share a 'ping-pong' kinetic mechanism with similar Km for substrate (glucose-1-P) and cofactor (glucose-1,6-P2). Micromolar concentrations of fructose-1,6-P2 and glycerate-2,3-P2 inhibit both isoenzymes similarly. PGM2, but not PGM1, is affected by ribose monophosphates (ribose-1-P and ribose-5-P), which act as inhibitors vs. glucose-1,6-P2 and apparent activators vs. glucose-1-P.","method":"In vitro kinetic assays on purified human erythrocyte isoenzymes","journal":"Biochimie","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic kinetic characterization with substrate and inhibitor profiling; single lab but multiple substrates/conditions tested","pmids":["6240990"],"is_preprint":false},{"year":1993,"finding":"The classical human PGM1 isozyme polymorphism is generated by only two point mutations: a C→T transition at nt 723 (Arg→Cys at residue 220, responsible for the PGM1 2/1 polymorphism) and a C→T transition at nt 1320 (Tyr→His at residue 419, responsible for the PGM1 +/- polymorphism). One of the four common alleles must have arisen by homologous intragenic recombination between these two mutation sites.","method":"DNA sequencing of the entire PGM1 coding region in individuals of known protein phenotype","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing with complete phenotype-genotype concordance, clear molecular mechanism established","pmids":["7902568"],"is_preprint":false},{"year":2019,"finding":"PGM1 catalyzes the interconversion of glucose-6-P and glucose-1-P, and its deficiency impairs both glycogen metabolism and glycosylation by depleting glucose-1-P, UDP-glucose, and UDP-galactose needed for ER- and Golgi-linked glycosylation. Tracer-based metabolomics in PGM1-CDG patient fibroblasts showed that galactose treatment replenishes galactose-1-P, UDP-glucose, and UDP-galactose, metabolically re-wiring sugar metabolism and restoring glycan synthesis.","method":"Tracer-based metabolomics in patient fibroblasts; incorporation of galactose-derived label into mature de novo glycans","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — isotope tracer metabolomics with direct substrate/product quantification in patient-derived cells; multiple metabolic readouts","pmids":["30982613"],"is_preprint":false},{"year":2020,"finding":"Crystal structures of PGM1 isoform 2 (free enzyme and in complex with substrate G1P and product G6P) reveal the structural basis for substrate and product recognition. The structures show the longer N-terminal of isoform 2 and detailed ligand-binding interactions for the first time in human PGM1.","method":"X-ray crystallography (three crystal structures: apo, G1P-bound, G6P-bound)","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures with ligand complexes providing atomic-resolution mechanism; single lab but three orthogonal structural datasets","pmids":["32221390"],"is_preprint":false},{"year":2018,"finding":"Missense variants within a substrate-binding loop in domain 4 (D4) of PGM1 cause extreme impairment of enzymatic activity through loss of conserved ligand-binding interactions and reduced mobility of the D4 loop, due to perturbation of its conformational ensemble. These synergistic effects make this loop a hotspot for disease-related variants.","method":"Biochemical activity assays, crystal structures of PGM1 variants, and molecular dynamics computational studies","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro activity assays combined with crystal structures and computational dynamics; multiple orthogonal methods in one study","pmids":["30122451"],"is_preprint":false},{"year":2020,"finding":"Under glucose deprivation, AMPK activation induces HDAC8 phosphorylation, causing HDAC8 translocation from nucleus to cytoplasm, disrupting HDAC8-histone 3 binding, and consequently upregulating PGM1 expression. Elevated PGM1 supports lung cancer cell survival by sustaining glycolysis, the oxidative pentose phosphate pathway, and oxidative phosphorylation under glucose deprivation, and mediates aberrant expression of metabolic enzymes via ERK1/2.","method":"AMPK activation/inhibition experiments, HDAC8 phosphorylation assays, nuclear-cytoplasmic fractionation, ChIP, PGM1 knockdown/overexpression in lung cancer cells with metabolic flux measurements","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis with cellular fractionation and metabolic readouts; single lab with multiple orthogonal approaches","pmids":["32171858"],"is_preprint":false},{"year":2023,"finding":"In a cardiomyocyte-specific conditional Pgm2 (mouse ortholog of human PGM1) knockout mouse model, loss of PGM1 causes dilated cardiomyopathy with reduced ejection fraction, excess glycogen accumulation, fibrosis, Z-disk disarray, swollen/fragmented mitochondria, decreased mitochondrial function, and broad glycosylation changes including significant alterations in sarcolemmal proteins (e.g., laminin-211 subunits). AAV9-mediated PGM1 gene replacement prevented and halted DCM progression.","method":"Conditional cardiomyocyte-specific knockout mouse, echocardiography, histology, ultrastructural analysis, transcriptomics, proteomics, glycoproteomics, AAV9 gene therapy rescue","journal":"Translational research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with defined cardiac phenotype, multiple orthogonal molecular readouts (transcriptomics, proteomics, glycoproteomics), and rescue by gene therapy","pmids":["36709920"],"is_preprint":false},{"year":2023,"finding":"In Pgm1 knockout C2C12 myoblasts, loss of PGM1 impairs maturation to myotubes. Dynamic flux analysis using 13C6-galactose revealed a block in the use of galactose for energy production. Knockout cells showed lower basal respiration and mitochondrial ATP production capacity, which were not restored by D-galactose supplementation, indicating a glycosylation-independent energy deficit.","method":"CRISPR/Cas9 knockout of Pgm1 in C2C12 myoblasts, 13C6-galactose tracer metabolomics, mitochondrial respiration assays (Seahorse)","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — genetic KO with isotope tracer metabolomics and direct mitochondrial function measurement; multiple orthogonal methods in one study","pmids":["37175952"],"is_preprint":false},{"year":2015,"finding":"DCM in PGM1-CDG can develop as a consequence of impaired binding of PGM1 to the heart-specific isoform of ZASP (LDB3), a sarcomeric Z-disk protein, independently of overall glycosylation efficiency. Thus, even when PGM1 mutations impair the ZASP-PGM1 complex, galactose supplementation cannot be expected to restore that function.","method":"Clinical molecular analysis; mechanistic inference from mutations affecting PGM1-ZASP interaction independently of glycosylation phenotype","journal":"JIMD reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic inference from patient data without direct biochemical confirmation of the interaction in this paper; single clinical case series","pmids":["26303607"],"is_preprint":false},{"year":2024,"finding":"The disease-associated PGM1 variant L516P is insoluble, catalytically inactive, forms aggregates in S. cerevisiae, and is rapidly ubiquitylated and degraded by the proteasome. Both the aggregation pattern and abundance of PGM1 L516P are chaperone-dependent, indicating that destabilized disease-linked PGM1 variants are subject to protein quality control (PQC)-linked degradation.","method":"Yeast-based solubility and activity assays, ubiquitylation assays, proteasome inhibitor experiments, chaperone dependency experiments, computational saturation mutagenesis","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro/yeast functional assays for insolubility, ubiquitylation, and proteasomal degradation; single lab with multiple orthogonal approaches","pmids":["38743592"],"is_preprint":false},{"year":2024,"finding":"Sec13 forms a protein complex with PGM1 and Ubqln1 (an ubiquitin ligase). Sec13 inhibits Ubqln1-mediated ubiquitination of PGM1, thereby stabilizing PGM1 and sustaining glycolysis (G6P production) in acute lung injury. Knockdown of Sec13 decreased PGM1 levels and reduced glycolytic output.","method":"Co-immunoprecipitation, protein complex analysis, ubiquitination assays, Sec13 and Pgm1 knockdown with metabolic readouts (lactate, G6P) in ALI mouse and cell models","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP establishing the Sec13-PGM1-Ubqln1 complex, ubiquitination assays, knockdown phenotype; single lab","pmids":["39159700"],"is_preprint":false},{"year":2025,"finding":"PGM1-deficient iPSC-derived cardiomyocytes (iCMs) exhibit reduced beating frequency, impaired contractility, and prolonged contraction kinetics. Proteomic analysis revealed depletion of Z-disk components including LDB3 (ZASP). AlphaFold3 structural modeling predicted a direct PGM1-LDB3 interaction, which was confirmed by in vitro binding assay. Mitochondrial proteins were severely depleted, mitochondrial respiration was impaired, and extensive metabolic rewiring with energy depletion was demonstrated by tracer metabolomics.","method":"iPSC-derived cardiomyocytes from patient fibroblasts, multielectrode array (MEA) recordings, untargeted (glyco)proteomics, AlphaFold3 structural modeling, in vitro binding confirmation, tracer metabolomics, mitochondrial respiration assays","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived iCM model with multiple orthogonal functional and molecular readouts; PGM1-LDB3 interaction confirmed in vitro; single lab","pmids":["41723528"],"is_preprint":false},{"year":2022,"finding":"PGM1 suppresses colorectal cancer cell migration and invasion, and its overexpression inhibits cell proliferation and promotes apoptosis; these effects are mediated via the PI3K/AKT signaling pathway.","method":"PGM1 knockdown and overexpression in CRC cell lines, Transwell migration/invasion assays, PI3K/AKT pathway analysis, in vivo tumor formation","journal":"Cancer cell international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional KD/OE with pathway placement via inhibitor studies; single lab, no reconstitution or structural data","pmids":["35614441"],"is_preprint":false},{"year":2025,"finding":"IRF6 inhibits PGM1 expression by decreasing the transcriptional activity of promoter 3 of PGM1, as shown by ChIP and dual-luciferase reporter assays. PGM1 overexpression reverses the inhibitory effects of IRF6 on neuroblastoma cell proliferation and glycolysis. Additionally, the E3 ligase TRIM59 mediates polyubiquitination and degradation of IRF6, thereby relieving IRF6-mediated transcriptional repression of PGM1.","method":"RNA sequencing, ChIP, dual-luciferase reporter assays, IRF6/PGM1 overexpression and knockdown, in vitro and in vivo proliferation and glycolysis assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and dual-luciferase assay establishing direct transcriptional regulation of PGM1 by IRF6; epistasis confirmed by rescue experiment; single lab","pmids":["40796729"],"is_preprint":false},{"year":1997,"finding":"In the erythroleukaemic K562 cell line, complete absence of PGM1 enzyme activity and immunoreactive protein is associated with very low levels of apparently full-length PGM1 mRNA, despite the presence of structurally intact PGM1 gene copies on chromosomes 1. This indicates that PGM1 deficiency in K562 is caused by abnormal regulation of transcription rather than gene deletion or gross rearrangement.","method":"Isoelectric focusing/activity staining, immunoblot with monospecific anti-PGM1 antibodies, FISH, Southern blot, RT-PCR","journal":"Annals of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal molecular methods (protein, RNA, DNA levels) ruling out structural causes and implicating transcriptional regulation; single lab","pmids":["9177117"],"is_preprint":false}],"current_model":"PGM1 is an evolutionarily conserved α-D-phosphohexomutase that catalyzes the reversible interconversion of glucose-1-phosphate and glucose-6-phosphate via a ping-pong kinetic mechanism; its activity is essential for glycogen metabolism, glycolysis, and cytoplasmic nucleotide sugar biosynthesis for N-glycosylation, with its classical protein polymorphism arising from two point mutations (R220C and Y419H) and intragenic recombination, its substrate-binding D4 loop being a hotspot for disease-associated variants that impair ligand binding and loop dynamics, its expression regulated transcriptionally by IRF6 (repressor) and post-translationally by Sec13-Ubqln1-mediated ubiquitination and by AMPK-HDAC8 signaling under glucose deprivation, and its non-enzymatic interaction with the Z-disk protein LDB3/ZASP linking it to sarcomere integrity and mitochondrial function in cardiomyocytes independently of glycosylation."},"narrative":{"mechanistic_narrative":"PGM1 is an α-D-phosphohexomutase that catalyzes the reversible interconversion of glucose-1-phosphate and glucose-6-phosphate through a ping-pong kinetic mechanism, positioning it at a metabolic branch point that supplies both glycogen metabolism and the nucleotide-sugar pool (UDP-glucose, UDP-galactose) required for ER- and Golgi-linked glycosylation [PMID:6240990, PMID:30982613, PMID:32221390]. Crystal structures of free enzyme and of G1P- and G6P-bound complexes define the substrate-binding architecture, and missense variants clustering in the domain-4 (D4) substrate-binding loop abolish activity by disrupting conserved ligand contacts and constraining loop mobility, making this loop a disease-variant hotspot [PMID:32221390, PMID:30122451]. Loss of PGM1 function causes a congenital disorder of glycosylation in which depletion of glucose-1-phosphate impairs both glycogen handling and glycan synthesis; galactose supplementation metabolically re-wires sugar flux to replenish UDP-galactose and restore glycan synthesis [PMID:30982613]. Beyond its catalytic role, PGM1 is required for cardiac and muscle integrity: cardiomyocyte-specific knockout produces dilated cardiomyopathy with glycogen accumulation, Z-disk disarray, and mitochondrial dysfunction rescuable by gene replacement, and PGM1 deficiency impairs myotube maturation and mitochondrial respiration in a manner not corrected by galactose, indicating a glycosylation-independent energy and structural deficit [PMID:36709920, PMID:37175952, PMID:41723528]. This non-enzymatic role is linked to a direct interaction with the Z-disk protein LDB3/ZASP [PMID:41723528]. PGM1 abundance is controlled transcriptionally — repressed by IRF6 acting on promoter 3 [PMID:40796729] — and post-translationally, with destabilized variants cleared by proteasomal protein quality control [PMID:38743592] and the enzyme stabilized within a Sec13–Ubqln1 complex that restrains its ubiquitination [PMID:39159700]. Under glucose deprivation, AMPK–HDAC8 signaling upregulates PGM1 to sustain glycolysis and oxidative metabolism in cancer cells [PMID:32171858].","teleology":[{"year":1984,"claim":"Established the catalytic and regulatory behavior of PGM1 as a phosphohexomutase, distinguishing it kinetically from PGM2 and defining its substrate, cofactor, and inhibitor profile.","evidence":"In vitro kinetic assays on purified human erythrocyte isoenzymes","pmids":["6240990"],"confidence":"High","gaps":["No structural basis for the kinetic mechanism","Cellular and physiological role not addressed"]},{"year":1993,"claim":"Resolved the molecular origin of the classical PGM1 protein polymorphism, showing it arises from two point mutations plus intragenic recombination rather than multiple independent loci.","evidence":"DNA sequencing of the entire coding region in individuals of known protein phenotype","pmids":["7902568"],"confidence":"High","gaps":["Functional consequences of the polymorphic residues not characterized","No disease association established for the common alleles"]},{"year":1997,"claim":"Showed that PGM1 deficiency can arise from transcriptional dysregulation rather than gene loss, implicating regulation of expression as a determinant of enzyme availability.","evidence":"Activity staining, immunoblot, FISH, Southern blot, and RT-PCR in K562 erythroleukemic cells","pmids":["9177117"],"confidence":"Medium","gaps":["Specific transcriptional regulators not identified","Mechanism of mRNA suppression unresolved"]},{"year":2015,"claim":"Proposed a glycosylation-independent route to PGM1-CDG cardiomyopathy via impaired binding to the Z-disk protein ZASP/LDB3, separating structural from metabolic disease mechanisms.","evidence":"Clinical molecular analysis with mechanistic inference from patient mutations","pmids":["26303607"],"confidence":"Low","gaps":["No direct biochemical confirmation of the PGM1-ZASP interaction in this study","Single clinical case series"]},{"year":2018,"claim":"Defined the D4 substrate-binding loop as a structural hotspot where disease variants abolish activity through combined loss of ligand contacts and reduced loop dynamics, linking genotype to enzymatic failure.","evidence":"Biochemical activity assays, crystal structures of variants, and molecular dynamics","pmids":["30122451"],"confidence":"High","gaps":["Does not address non-catalytic functions of the protein","In vivo consequences of D4 variants not tested"]},{"year":2019,"claim":"Mechanistically connected PGM1 deficiency to dual impairment of glycogen metabolism and glycosylation, and explained galactose therapy as metabolic re-wiring that replenishes UDP-sugars.","evidence":"Tracer-based metabolomics and de novo glycan labeling in patient fibroblasts","pmids":["30982613"],"confidence":"High","gaps":["Does not explain glycosylation-independent phenotypes","Tissue-specific differences in metabolic rescue not addressed"]},{"year":2020,"claim":"Provided atomic-resolution views of human PGM1 with substrate and product bound, defining the structural basis of substrate and product recognition.","evidence":"X-ray crystallography of apo, G1P-bound, and G6P-bound enzyme","pmids":["32221390"],"confidence":"High","gaps":["Catalytic intermediate states not captured","No structural information on regulatory interactions"]},{"year":2020,"claim":"Placed PGM1 downstream of AMPK–HDAC8 signaling as a stress-induced metabolic effector supporting cancer cell survival under glucose deprivation.","evidence":"AMPK and HDAC8 perturbation, ChIP, fractionation, and metabolic flux in lung cancer cells","pmids":["32171858"],"confidence":"Medium","gaps":["Direct HDAC8 occupancy at the PGM1 locus versus indirect effects not fully separated","Generality beyond lung cancer untested"]},{"year":2022,"claim":"Suggested a tumor-suppressive role for PGM1 in colorectal cancer acting through PI3K/AKT signaling.","evidence":"Knockdown/overexpression, migration/invasion assays, and pathway analysis in CRC lines with in vivo tumor assays","pmids":["35614441"],"confidence":"Low","gaps":["Pathway placement based on inhibitor studies without reconstitution","Mechanistic link between catalytic activity and PI3K/AKT unclear"]},{"year":2023,"claim":"Established a causal in vivo requirement for PGM1 in cardiac integrity, demonstrating dilated cardiomyopathy on loss and rescue by gene replacement.","evidence":"Cardiomyocyte-specific conditional knockout mouse with echocardiography, ultrastructure, multi-omics, and AAV9 gene therapy","pmids":["36709920"],"confidence":"High","gaps":["Does not separate metabolic from structural contributions to the phenotype","Mechanism linking PGM1 loss to mitochondrial fragmentation unresolved"]},{"year":2023,"claim":"Demonstrated a glycosylation-independent energy deficit upon PGM1 loss, showing impaired galactose-fueled respiration and myotube maturation not corrected by galactose.","evidence":"CRISPR knockout in C2C12 myoblasts with 13C-galactose tracing and Seahorse respirometry","pmids":["37175952"],"confidence":"High","gaps":["Molecular basis of the mitochondrial defect not defined","Does not identify the non-metabolic effector responsible"]},{"year":2024,"claim":"Showed that destabilized disease variants are eliminated by chaperone-dependent proteasomal quality control, defining a degradation route for misfolded PGM1.","evidence":"Yeast solubility/activity, ubiquitylation, proteasome inhibition, and chaperone-dependency assays with computational mutagenesis","pmids":["38743592"],"confidence":"Medium","gaps":["Human E3 ligases and chaperones for PGM1 not identified","Conducted in a yeast heterologous system"]},{"year":2024,"claim":"Identified a Sec13–PGM1–Ubqln1 complex in which Sec13 stabilizes PGM1 by restraining its ubiquitination, linking PGM1 abundance to glycolytic output in acute lung injury.","evidence":"Co-immunoprecipitation, ubiquitination assays, and knockdown with metabolic readouts in ALI models","pmids":["39159700"],"confidence":"Medium","gaps":["Ubqln1 ubiquitination of PGM1 not reconstituted","Single lab without independent confirmation"]},{"year":2025,"claim":"Confirmed a direct PGM1-LDB3 interaction and tied PGM1 deficiency to contractile, Z-disk, and mitochondrial defects in patient-derived cardiomyocytes, substantiating the non-enzymatic structural role.","evidence":"Patient iPSC-derived cardiomyocytes with MEA recordings, glycoproteomics, AlphaFold3 modeling, in vitro binding, and tracer metabolomics","pmids":["41723528"],"confidence":"Medium","gaps":["Interaction interface and affinity not quantified","Causal contribution of LDB3 binding versus metabolic deficit not dissected"]},{"year":2025,"claim":"Identified IRF6 as a direct transcriptional repressor of PGM1 via promoter 3, with TRIM59-mediated IRF6 degradation relieving repression to drive glycolysis in neuroblastoma.","evidence":"RNA-seq, ChIP, dual-luciferase reporters, and overexpression/knockdown rescue in vitro and in vivo","pmids":["40796729"],"confidence":"Medium","gaps":["Generality of IRF6-PGM1 regulation beyond neuroblastoma untested","Interplay with AMPK-HDAC8 regulation unexplored"]},{"year":null,"claim":"How the catalytic (glycosylation/glycogen) and non-enzymatic (Z-disk/LDB3, mitochondrial) functions of PGM1 are mechanistically separated and coordinated in muscle and heart remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the PGM1-LDB3 interface at residue resolution","Mechanism linking PGM1 loss to mitochondrial fragmentation undefined","Unknown whether disease variants disrupt catalysis, structural binding, or both"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016853","term_label":"isomerase activity","supporting_discovery_ids":[0,2,3,4]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,5,7]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,6]}],"complexes":["Sec13-PGM1-Ubqln1 complex"],"partners":["LDB3","SEC13","UBQLN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P36871","full_name":"Phosphoglucomutase-1","aliases":["Glucose phosphomutase 1"],"length_aa":562,"mass_kda":61.4,"function":"Catalyzes the reversible isomerization of alpha-D-glucose 1-phosphate to alpha-D-glucose 6-phosphate (PubMed:15378030, PubMed:25288802). The mechanism proceeds via the intermediate compound alpha-D-glucose 1,6-bisphosphate (Probable) (PubMed:25288802). This enzyme participates in both the breakdown and synthesis of glucose (PubMed:17924679, PubMed:25288802)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P36871/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PGM1","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SAR1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PGM1","total_profiled":1310},"omim":[{"mim_id":"617164","title":"SHORT STATURE-MICROGNATHIA SYNDROME; SSMG","url":"https://www.omim.org/entry/617164"},{"mim_id":"615356","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18; LGMDR18","url":"https://www.omim.org/entry/615356"},{"mim_id":"614921","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T","url":"https://www.omim.org/entry/614921"},{"mim_id":"613789","title":"COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2","url":"https://www.omim.org/entry/613789"},{"mim_id":"612280","title":"FUCOSIDASE, ALPHA-L, 1; FUCA1","url":"https://www.omim.org/entry/612280"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":1460.8},{"tissue":"tongue","ntpm":735.9}],"url":"https://www.proteinatlas.org/search/PGM1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P36871","domains":[{"cath_id":"3.40.120.10","chopping":"6-191","consensus_level":"high","plddt":97.4875,"start":6,"end":191},{"cath_id":"3.40.120.10","chopping":"195-421","consensus_level":"medium","plddt":98.2886,"start":195,"end":421},{"cath_id":"3.30.310.50","chopping":"423-562","consensus_level":"high","plddt":94.9601,"start":423,"end":562}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36871","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36871-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36871-F1-predicted_aligned_error_v6.png","plddt_mean":97.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PGM1","jax_strain_url":"https://www.jax.org/strain/search?query=PGM1"},"sequence":{"accession":"P36871","fasta_url":"https://rest.uniprot.org/uniprotkb/P36871.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36871/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36871"}},"corpus_meta":[{"pmid":"7684194","id":"PMC_7684194","title":"PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule.","date":"1993","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7684194","citation_count":286,"is_preprint":false},{"pmid":"15194571","id":"PMC_15194571","title":"Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry.","date":"2004","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15194571","citation_count":129,"is_preprint":false},{"pmid":"622823","id":"PMC_622823","title":"Genetic evidence for four common alleles at the phosphoglucomutase-1 locus (PGM1) detectable by isoelectric focusing.","date":"1978","source":"Vox sanguinis","url":"https://pubmed.ncbi.nlm.nih.gov/622823","citation_count":100,"is_preprint":false},{"pmid":"844869","id":"PMC_844869","title":"Evidence for two additional common alleles at the PGM1 locus (phosphoglucomutase--E.C.: 2.7.5.1). A comparison by three different techniques.","date":"1977","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/844869","citation_count":92,"is_preprint":false},{"pmid":"30982613","id":"PMC_30982613","title":"The Metabolic Map into the Pathomechanism and Treatment of PGM1-CDG.","date":"2019","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30982613","citation_count":67,"is_preprint":false},{"pmid":"32171858","id":"PMC_32171858","title":"AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32171858","citation_count":57,"is_preprint":false},{"pmid":"32681750","id":"PMC_32681750","title":"International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management.","date":"2020","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/32681750","citation_count":54,"is_preprint":false},{"pmid":"1636247","id":"PMC_1636247","title":"Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: an immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies.","date":"1992","source":"Virchows Archiv. A, Pathological anatomy and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/1636247","citation_count":53,"is_preprint":false},{"pmid":"29052596","id":"PMC_29052596","title":"t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/29052596","citation_count":52,"is_preprint":false},{"pmid":"8491475","id":"PMC_8491475","title":"Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1.","date":"1993","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8491475","citation_count":49,"is_preprint":false},{"pmid":"28190645","id":"PMC_28190645","title":"PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose.","date":"2017","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/28190645","citation_count":39,"is_preprint":false},{"pmid":"24878975","id":"PMC_24878975","title":"Glycogen storage disease-like phenotype with central nervous system involvement in a PGM1-CDG patient.","date":"2014","source":"Neuro endocrinology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24878975","citation_count":33,"is_preprint":false},{"pmid":"738719","id":"PMC_738719","title":"PGM1 subtyping by means of acid starch gel electrophoresis.","date":"1978","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/738719","citation_count":33,"is_preprint":false},{"pmid":"2950811","id":"PMC_2950811","title":"Further data on chromosomal assignments of pig enzyme loci LDHA, LDHB, MPI, PEPB and PGM1, using somatic cell hybrids.","date":"1986","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2950811","citation_count":29,"is_preprint":false},{"pmid":"6219939","id":"PMC_6219939","title":"Some genetic implications of isoelectric focusing of human red cell phosphoglucomutase (PGM1) and serum protein group specific component (Gc): genetic diversity in the populations of Himachal Pradesh, India.","date":"1983","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6219939","citation_count":27,"is_preprint":false},{"pmid":"7902568","id":"PMC_7902568","title":"The classical human phosphoglucomutase (PGM1) isozyme polymorphism is generated by intragenic recombination.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7902568","citation_count":23,"is_preprint":false},{"pmid":"6455377","id":"PMC_6455377","title":"Isoelectric focusing of human red cell phosphoglucomutase (PGM1): phenotype distribution in the Swiss population - rare phenotypes.","date":"1981","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/6455377","citation_count":23,"is_preprint":false},{"pmid":"26303607","id":"PMC_26303607","title":"News on Clinical Details and Treatment in PGM1-CDG.","date":"2015","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/26303607","citation_count":22,"is_preprint":false},{"pmid":"34507580","id":"PMC_34507580","title":"Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34507580","citation_count":22,"is_preprint":false},{"pmid":"10441333","id":"PMC_10441333","title":"Mapping recombination hotspots in human phosphoglucomutase (PGM1).","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10441333","citation_count":22,"is_preprint":false},{"pmid":"6228152","id":"PMC_6228152","title":"Population distribution in North and Central America of PGM1 and Gc subtypes as determined by isoelectric focusing (IEF).","date":"1983","source":"American journal of physical anthropology","url":"https://pubmed.ncbi.nlm.nih.gov/6228152","citation_count":22,"is_preprint":false},{"pmid":"36709920","id":"PMC_36709920","title":"AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG).","date":"2023","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36709920","citation_count":20,"is_preprint":false},{"pmid":"6212529","id":"PMC_6212529","title":"PGM1 subtypes in Galicia (NW Spain).","date":"1982","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/6212529","citation_count":19,"is_preprint":false},{"pmid":"32221390","id":"PMC_32221390","title":"Structural basis for substrate and product recognition in human phosphoglucomutase-1 (PGM1) isoform 2, a member of the α-D-phosphohexomutase superfamily.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32221390","citation_count":18,"is_preprint":false},{"pmid":"457117","id":"PMC_457117","title":"Characterisation of the isoenzymes of phosphoglucomutase (PGM) determined by the first (PGM1) and second (PGM2) locus observed by isoelectric focusing.","date":"1979","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/457117","citation_count":18,"is_preprint":false},{"pmid":"7665162","id":"PMC_7665162","title":"Molecular mapping of SSRs for Pgm1 and C8b in the vicinity of the rat fatty locus.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7665162","citation_count":17,"is_preprint":false},{"pmid":"34043239","id":"PMC_34043239","title":"A new D-galactose treatment monitoring index for PGM1-CDG.","date":"2021","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/34043239","citation_count":16,"is_preprint":false},{"pmid":"31563034","id":"PMC_31563034","title":"The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy and unexpected sudden cardiac death in childhood.","date":"2019","source":"Forensic science international. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31563034","citation_count":16,"is_preprint":false},{"pmid":"30122451","id":"PMC_30122451","title":"A Hotspot for Disease-Associated Variants of Human PGM1 Is Associated with Impaired Ligand Binding and Loop Dynamics.","date":"2018","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30122451","citation_count":16,"is_preprint":false},{"pmid":"2842250","id":"PMC_2842250","title":"Confirmation of the assignment of MYCL to chromosome 1 in humans and its position relative to RH, UMPK, and PGM1.","date":"1988","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2842250","citation_count":16,"is_preprint":false},{"pmid":"6242834","id":"PMC_6242834","title":"Major morphological effects of a regulatory gene: Pgm1-t in rainbow trout.","date":"1984","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/6242834","citation_count":14,"is_preprint":false},{"pmid":"6218067","id":"PMC_6218067","title":"Isoelectric focusing studies of human red cell PGM1 in Japanese, with special reference to the characterization of PGM17.","date":"1982","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/6218067","citation_count":13,"is_preprint":false},{"pmid":"30262252","id":"PMC_30262252","title":"Central nervous involvement is common in PGM1-CDG.","date":"2018","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30262252","citation_count":12,"is_preprint":false},{"pmid":"37175952","id":"PMC_37175952","title":"In Vitro Skeletal Muscle Model of PGM1 Deficiency Reveals Altered Energy Homeostasis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37175952","citation_count":12,"is_preprint":false},{"pmid":"468082","id":"PMC_468082","title":"Studies on the frequencies of PGM1, PGM3 and Es-D types from hair roots in Japanese subjects and the determination of these types from old hair roots.","date":"1979","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/468082","citation_count":12,"is_preprint":false},{"pmid":"6240990","id":"PMC_6240990","title":"Human erythrocyte phosphoglucomutase: comparison of the kinetic properties of PGM1 and PGM2 isoenzymes.","date":"1984","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/6240990","citation_count":12,"is_preprint":false},{"pmid":"6449119","id":"PMC_6449119","title":"PGM1 subtypes determined by agarose gel isoelectrofocusing.","date":"1980","source":"Zeitschrift fur Rechtsmedizin. Journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6449119","citation_count":12,"is_preprint":false},{"pmid":"30737079","id":"PMC_30737079","title":"Congenital disorder of glycosylation type 1T with a novel truncated homozygous mutation in PGM1 gene and literature review.","date":"2019","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/30737079","citation_count":11,"is_preprint":false},{"pmid":"416891","id":"PMC_416891","title":"Relative positions of chromosome 1 loci Fy, PGM1, Sc, UMPK, Rh, PGD and ENO1 in man.","date":"1977","source":"Canadian journal of genetics and cytology. Journal canadien de genetique et de cytologie","url":"https://pubmed.ncbi.nlm.nih.gov/416891","citation_count":11,"is_preprint":false},{"pmid":"6462057","id":"PMC_6462057","title":"Subtyping of phosphoglucomutase locus 1 (PGM1) polymorphism in some populations of Rwanda: description of variant phenotypes, \"haplotype\" frequencies, and linkage disequilibrium data.","date":"1982","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6462057","citation_count":11,"is_preprint":false},{"pmid":"6453524","id":"PMC_6453524","title":"Isoelectric focusing of PGM1 (E.C.2.7.5.1) on agarose. Application to cases of disputed parentage.","date":"1981","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/6453524","citation_count":11,"is_preprint":false},{"pmid":"6451573","id":"PMC_6451573","title":"Subtypes of the phosphoglucomutase-1 (PGM1) locus detectable in Polish populations by isoelectric focusing on cellogel.","date":"1980","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6451573","citation_count":11,"is_preprint":false},{"pmid":"37181075","id":"PMC_37181075","title":"Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.","date":"2023","source":"Therapeutic advances in rare disease","url":"https://pubmed.ncbi.nlm.nih.gov/37181075","citation_count":10,"is_preprint":false},{"pmid":"29858906","id":"PMC_29858906","title":"Clinical and molecular genetic characterization of two patients with mutations in the phosphoglucomutase 1 (PGM1) gene.","date":"2018","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/29858906","citation_count":10,"is_preprint":false},{"pmid":"1300612","id":"PMC_1300612","title":"Macrophages (phagocytic-histiocytic reticular cells) in reactive-inflammatory lesions of the bone marrow and in myelodysplastic syndromes (MDS). An immunohistochemical and morphometric study by use of a new monoclonal antibody (PG-M1).","date":"1992","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/1300612","citation_count":10,"is_preprint":false},{"pmid":"36947965","id":"PMC_36947965","title":"Knock-down of PGM1 inhibits cell viability, glycolysis, and oxidative phosphorylation in glioma under low glucose condition via the Myc signaling pathway.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36947965","citation_count":9,"is_preprint":false},{"pmid":"9112249","id":"PMC_9112249","title":"The rat corpulent (cp) mutation maps to the same interval on (Pgm1-Glut1) rat chromosome 5 as the fatty (fa) mutation.","date":"1997","source":"Obesity research","url":"https://pubmed.ncbi.nlm.nih.gov/9112249","citation_count":9,"is_preprint":false},{"pmid":"12453296","id":"PMC_12453296","title":"Expression of the histiocytic marker PG-M1 in granuloma annulare and rheumatoid nodules of the skin.","date":"2002","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12453296","citation_count":9,"is_preprint":false},{"pmid":"2895061","id":"PMC_2895061","title":"The anonymous RFLP locus D1S2 is close to PGM1 on chromosome 1.","date":"1988","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/2895061","citation_count":9,"is_preprint":false},{"pmid":"2576634","id":"PMC_2576634","title":"Linkage of the Dao-1 gene for D-amino-acid oxidase to the pgm-1 gene for phosphoglucomutase-1 on the mouse chromosome 5.","date":"1989","source":"Idengaku zasshi","url":"https://pubmed.ncbi.nlm.nih.gov/2576634","citation_count":9,"is_preprint":false},{"pmid":"35614441","id":"PMC_35614441","title":"PGM1 suppresses colorectal cancer cell migration and invasion by regulating the PI3K/AKT pathway.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/35614441","citation_count":8,"is_preprint":false},{"pmid":"15509594","id":"PMC_15509594","title":"Recombination hotspots and block structure of linkage disequilibrium in the human genome exemplified by detailed analysis of PGM1 on 1p31.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15509594","citation_count":8,"is_preprint":false},{"pmid":"6217145","id":"PMC_6217145","title":"Isoelectric focusing of human red cell phosphoglucomutase (PGM1). Phenotype distribution in the population of Tuscany and two hereditary variants.","date":"1982","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6217145","citation_count":8,"is_preprint":false},{"pmid":"170193","id":"PMC_170193","title":"Chromosome no. 1 of man and chimpanzee: identity of gene mapping for three loci: PPH, PGM1, and Pep-C.","date":"1975","source":"Humangenetik","url":"https://pubmed.ncbi.nlm.nih.gov/170193","citation_count":8,"is_preprint":false},{"pmid":"10819019","id":"PMC_10819019","title":"Isoelectric focusing of red cell phosphoglucomutase (E.C.: 2.7.5.1) at the PGM1 locus in a French-Canadian population.","date":"1981","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10819019","citation_count":8,"is_preprint":false},{"pmid":"2682046","id":"PMC_2682046","title":"PGM-1: a transplantable murine leukemia of granulocyte-macrophage progenitor cells.","date":"1989","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/2682046","citation_count":8,"is_preprint":false},{"pmid":"6459984","id":"PMC_6459984","title":"A new hereditary variant of the PGM1 erythrocyte enzyme system determined by isoelectric focusing.","date":"1981","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6459984","citation_count":8,"is_preprint":false},{"pmid":"38164393","id":"PMC_38164393","title":"Functional identification of PGM1 in the regulating development and depositing of inosine monophosphate specific for myoblasts.","date":"2023","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/38164393","citation_count":7,"is_preprint":false},{"pmid":"6227274","id":"PMC_6227274","title":"Distribution of three red-cell enzyme polymorphisms (ACP, PGM1 and AK) in gypsies from Slovakia (Czechoslovakia).","date":"1983","source":"Annals of human biology","url":"https://pubmed.ncbi.nlm.nih.gov/6227274","citation_count":7,"is_preprint":false},{"pmid":"9682444","id":"PMC_9682444","title":"Regional localisations of VIM, HSD3b, ACTA1 and PGM1 in pigs.","date":"1998","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9682444","citation_count":7,"is_preprint":false},{"pmid":"447151","id":"PMC_447151","title":"Red cell PGM1 (phosphoglucomutase) phenotyping by isoelectric focussing and starch gel electrophoresis in cases of disputed paternity in the United Kingdom. An evaluation of the results obtained in 95 cases.","date":"1979","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/447151","citation_count":7,"is_preprint":false},{"pmid":"955634","id":"PMC_955634","title":"On the geographical variability of the red cell PGM1 and acid phosphatase gene frequencies.","date":"1976","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/955634","citation_count":7,"is_preprint":false},{"pmid":"6450158","id":"PMC_6450158","title":"Substrate affinity in PGM1, PGM2, and PGM2 isozymes.","date":"1980","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6450158","citation_count":6,"is_preprint":false},{"pmid":"8661695","id":"PMC_8661695","title":"Chromosome localization of the loci for PEPA, PEPB, PEPS, IDH1, GSR, MPI, PGM1, NP, SOD1, and ME1 in the common shrew (Sorex araneus).","date":"1996","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/8661695","citation_count":6,"is_preprint":false},{"pmid":"2944815","id":"PMC_2944815","title":"Phosphoglucomutase-1 subtypes: polymorphic occurrence of PGM1*7+ and geographical variation in Japan.","date":"1986","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/2944815","citation_count":6,"is_preprint":false},{"pmid":"38968673","id":"PMC_38968673","title":"Coagulation abnormalities and vascular complications are common in PGM1-CDG.","date":"2024","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38968673","citation_count":5,"is_preprint":false},{"pmid":"3159642","id":"PMC_3159642","title":"Gene localisation of the PGM1 enzyme system and the Duffy blood groups on chromosome No. 1 by means of a new fragile site at 1p31.","date":"1985","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3159642","citation_count":5,"is_preprint":false},{"pmid":"10738524","id":"PMC_10738524","title":"Identification and characterisation of polymorphisms in human phosphoglucomutase (PGM1).","date":"1999","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10738524","citation_count":5,"is_preprint":false},{"pmid":"37042760","id":"PMC_37042760","title":"Unique clinical presentations and follow-up outcomes from experience with congenital disorders of glycosylation: PMM2-PGM1-DPAGT1-MPI-POMT2-B3GALNT2-DPM1-SRD5A3-CDG.","date":"2023","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/37042760","citation_count":5,"is_preprint":false},{"pmid":"6237043","id":"PMC_6237043","title":"6PGD and PGM1 polymorphisms in south Sardinia.","date":"1984","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/6237043","citation_count":5,"is_preprint":false},{"pmid":"6210999","id":"PMC_6210999","title":"Isoelectric focusing studies on the PGM1 subtypes in the northern Japanese population.","date":"1982","source":"Zeitschrift fur Rechtsmedizin. Journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6210999","citation_count":5,"is_preprint":false},{"pmid":"2941351","id":"PMC_2941351","title":"Red cell phosphoglucomutase (PGM1) subtypes in Egyptians.","date":"1986","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/2941351","citation_count":4,"is_preprint":false},{"pmid":"1831778","id":"PMC_1831778","title":"[Genetic studies of phosphoglucomutase-1 (PGM1) subtypes: population aspects].","date":"1991","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/1831778","citation_count":4,"is_preprint":false},{"pmid":"3157638","id":"PMC_3157638","title":"Phosphoglucomutase (PGM1) subtypes in a Finnish population determined by isoelectric focusing in agarose gel.","date":"1985","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/3157638","citation_count":4,"is_preprint":false},{"pmid":"9177117","id":"PMC_9177117","title":"Molecular and cytological investigations of phosphoglucomutase (PGM1) in the K562 cell line.","date":"1997","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9177117","citation_count":3,"is_preprint":false},{"pmid":"6457529","id":"PMC_6457529","title":"Subtyping of human red cell phosphoglucomutase locus 1 (PGM1) polymorphism: a third PGM1(1) allele common among Twa Pygmies from North Rwanda.","date":"1981","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6457529","citation_count":3,"is_preprint":false},{"pmid":"468263","id":"PMC_468263","title":"Differential function of the phosphoglucomutase isozymes PGM1 and PGM2.","date":"1979","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/468263","citation_count":3,"is_preprint":false},{"pmid":"6447424","id":"PMC_6447424","title":"[Frequencies of red cell enzyme polymorphisms acP, ADA, AK, EsD, 6-PGD, and PGM1 determined by parallel investigations of Turks and Germans living in the Lübeck area (author's transl)].","date":"1980","source":"Zeitschrift fur Rechtsmedizin. Journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6447424","citation_count":3,"is_preprint":false},{"pmid":"2155993","id":"PMC_2155993","title":"Evaluation of a nonequilibrium isoelectric focusing (IEF) method for the simultaneous typing of esterase D (EsD), red cell acid phosphatase (AcP1), phosphoglucomutase (PGM1), adenylate kinase (AK), and adenosine deaminase (ADA).","date":"1990","source":"Journal of forensic sciences","url":"https://pubmed.ncbi.nlm.nih.gov/2155993","citation_count":3,"is_preprint":false},{"pmid":"2946235","id":"PMC_2946235","title":"PGM1 subtype polymorphism in 14 endogamous Dravidian-speaking populations of South India.","date":"1986","source":"American journal of physical anthropology","url":"https://pubmed.ncbi.nlm.nih.gov/2946235","citation_count":3,"is_preprint":false},{"pmid":"40631269","id":"PMC_40631269","title":"PGM1 deficiency disrupts sarcomere and mitochondrial function in a stem-cell cardiomyocyte model.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40631269","citation_count":2,"is_preprint":false},{"pmid":"40358162","id":"PMC_40358162","title":"Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/40358162","citation_count":2,"is_preprint":false},{"pmid":"7034636","id":"PMC_7034636","title":"Geographic and ethnic distribution of genetic markers in India. 2. Inv, Gm, Gc, ADA, AK, ap, PGM1, 6-PGD and EsD polymorphisms.","date":"1981","source":"Anthropologischer Anzeiger; Bericht uber die biologisch-anthropologische Literatur","url":"https://pubmed.ncbi.nlm.nih.gov/7034636","citation_count":2,"is_preprint":false},{"pmid":"6192713","id":"PMC_6192713","title":"PGM1 and Gc subtype gene frequencies in a California Hispanic population.","date":"1983","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6192713","citation_count":2,"is_preprint":false},{"pmid":"11758695","id":"PMC_11758695","title":"Identification of base substitutions in ten types of rare variants of phosphoglucomutase-1 (PGM1) encountered in Japanese.","date":"2001","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/11758695","citation_count":2,"is_preprint":false},{"pmid":"6452267","id":"PMC_6452267","title":"Red cell phosphoglucomutase (PGM)-deficiency: hereditary defect of the PGM1-locus.","date":"1981","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/6452267","citation_count":2,"is_preprint":false},{"pmid":"2935481","id":"PMC_2935481","title":"A new partially deficient variant in the phosphoglucomutase 1 system, PGM1*W31.","date":"1986","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2935481","citation_count":2,"is_preprint":false},{"pmid":"38743592","id":"PMC_38743592","title":"Destabilization and Degradation of a Disease-Linked PGM1 Protein Variant.","date":"2024","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38743592","citation_count":1,"is_preprint":false},{"pmid":"40796729","id":"PMC_40796729","title":"Degradation of IRF6 by TRIM59 in tumor cells triggers PGM1-mediated glycolysis to regulate cell proliferation in neuroblastoma.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40796729","citation_count":1,"is_preprint":false},{"pmid":"25867431","id":"PMC_25867431","title":"Molecular characterization, expression patterns, and promoter activity analysis of PGM1 in pigs.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/25867431","citation_count":1,"is_preprint":false},{"pmid":"39159700","id":"PMC_39159700","title":"Sec13 promotes glycolysis by inhibiting Ubqln1 mediated Pgm1 ubiquitination in ALI.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39159700","citation_count":1,"is_preprint":false},{"pmid":"1299311","id":"PMC_1299311","title":"Distribution of PGM1 subtypes in 12 populations of China.","date":"1992","source":"Gene geography : a computerized bulletin on human gene frequencies","url":"https://pubmed.ncbi.nlm.nih.gov/1299311","citation_count":1,"is_preprint":false},{"pmid":"1840292","id":"PMC_1840292","title":"ESD, GLO1, PGD, PGM1 and PGM2 gene frequencies in the Salerno Province (Italy).","date":"1991","source":"Gene geography : a computerized bulletin on human gene frequencies","url":"https://pubmed.ncbi.nlm.nih.gov/1840292","citation_count":1,"is_preprint":false},{"pmid":"35205251","id":"PMC_35205251","title":"Balanced Polymorphism at the Pgm-1 Locus of the Pompeii Worm Alvinella pompejana and Its Variant Adaptability Is Only Governed by Two QE Mutations at Linked Sites.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35205251","citation_count":1,"is_preprint":false},{"pmid":"1840293","id":"PMC_1840293","title":"Genetic polymorphism at the phosphoglucomutase 1 (PGM1) locus in Cosenza Province (Calabria--southern Italy).","date":"1991","source":"Gene geography : a computerized bulletin on human gene frequencies","url":"https://pubmed.ncbi.nlm.nih.gov/1840293","citation_count":1,"is_preprint":false},{"pmid":"6242530","id":"PMC_6242530","title":"Population genetic studies of PI, Tf, Gc and PGM1 subtypes among various caste groups in North India.","date":"1984","source":"Acta anthropogenetica","url":"https://pubmed.ncbi.nlm.nih.gov/6242530","citation_count":1,"is_preprint":false},{"pmid":"2138584","id":"PMC_2138584","title":"Demonstration of incompatible mother-child pairs in PGM1 and Duffy systems in a three-generation family from the upper Silesia (Poland).","date":"1990","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/2138584","citation_count":1,"is_preprint":false},{"pmid":"3158586","id":"PMC_3158586","title":"PGM1 null allele detected in a Caucasian mother-son pair.","date":"1985","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/3158586","citation_count":1,"is_preprint":false},{"pmid":"41723528","id":"PMC_41723528","title":"PGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes.","date":"2026","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41723528","citation_count":0,"is_preprint":false},{"pmid":"2534281","id":"PMC_2534281","title":"[Distributions and gene frequencies of PGM1 subtype, EsD, GLO1, AK, ADAand 6-PGD in 20 races of China].","date":"1989","source":"Yi chuan xue bao = Acta genetica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/2534281","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41336,"output_tokens":4252,"usd":0.093894,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12227,"output_tokens":4491,"usd":0.086705,"stage2_stop_reason":"end_turn"},"total_usd":0.180599,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"PGM1 and PGM2 isoenzymes share a 'ping-pong' kinetic mechanism with similar Km for substrate (glucose-1-P) and cofactor (glucose-1,6-P2). Micromolar concentrations of fructose-1,6-P2 and glycerate-2,3-P2 inhibit both isoenzymes similarly. PGM2, but not PGM1, is affected by ribose monophosphates (ribose-1-P and ribose-5-P), which act as inhibitors vs. glucose-1,6-P2 and apparent activators vs. glucose-1-P.\",\n      \"method\": \"In vitro kinetic assays on purified human erythrocyte isoenzymes\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic kinetic characterization with substrate and inhibitor profiling; single lab but multiple substrates/conditions tested\",\n      \"pmids\": [\"6240990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The classical human PGM1 isozyme polymorphism is generated by only two point mutations: a C→T transition at nt 723 (Arg→Cys at residue 220, responsible for the PGM1 2/1 polymorphism) and a C→T transition at nt 1320 (Tyr→His at residue 419, responsible for the PGM1 +/- polymorphism). One of the four common alleles must have arisen by homologous intragenic recombination between these two mutation sites.\",\n      \"method\": \"DNA sequencing of the entire PGM1 coding region in individuals of known protein phenotype\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing with complete phenotype-genotype concordance, clear molecular mechanism established\",\n      \"pmids\": [\"7902568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PGM1 catalyzes the interconversion of glucose-6-P and glucose-1-P, and its deficiency impairs both glycogen metabolism and glycosylation by depleting glucose-1-P, UDP-glucose, and UDP-galactose needed for ER- and Golgi-linked glycosylation. Tracer-based metabolomics in PGM1-CDG patient fibroblasts showed that galactose treatment replenishes galactose-1-P, UDP-glucose, and UDP-galactose, metabolically re-wiring sugar metabolism and restoring glycan synthesis.\",\n      \"method\": \"Tracer-based metabolomics in patient fibroblasts; incorporation of galactose-derived label into mature de novo glycans\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — isotope tracer metabolomics with direct substrate/product quantification in patient-derived cells; multiple metabolic readouts\",\n      \"pmids\": [\"30982613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structures of PGM1 isoform 2 (free enzyme and in complex with substrate G1P and product G6P) reveal the structural basis for substrate and product recognition. The structures show the longer N-terminal of isoform 2 and detailed ligand-binding interactions for the first time in human PGM1.\",\n      \"method\": \"X-ray crystallography (three crystal structures: apo, G1P-bound, G6P-bound)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures with ligand complexes providing atomic-resolution mechanism; single lab but three orthogonal structural datasets\",\n      \"pmids\": [\"32221390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Missense variants within a substrate-binding loop in domain 4 (D4) of PGM1 cause extreme impairment of enzymatic activity through loss of conserved ligand-binding interactions and reduced mobility of the D4 loop, due to perturbation of its conformational ensemble. These synergistic effects make this loop a hotspot for disease-related variants.\",\n      \"method\": \"Biochemical activity assays, crystal structures of PGM1 variants, and molecular dynamics computational studies\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro activity assays combined with crystal structures and computational dynamics; multiple orthogonal methods in one study\",\n      \"pmids\": [\"30122451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Under glucose deprivation, AMPK activation induces HDAC8 phosphorylation, causing HDAC8 translocation from nucleus to cytoplasm, disrupting HDAC8-histone 3 binding, and consequently upregulating PGM1 expression. Elevated PGM1 supports lung cancer cell survival by sustaining glycolysis, the oxidative pentose phosphate pathway, and oxidative phosphorylation under glucose deprivation, and mediates aberrant expression of metabolic enzymes via ERK1/2.\",\n      \"method\": \"AMPK activation/inhibition experiments, HDAC8 phosphorylation assays, nuclear-cytoplasmic fractionation, ChIP, PGM1 knockdown/overexpression in lung cancer cells with metabolic flux measurements\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis with cellular fractionation and metabolic readouts; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"32171858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In a cardiomyocyte-specific conditional Pgm2 (mouse ortholog of human PGM1) knockout mouse model, loss of PGM1 causes dilated cardiomyopathy with reduced ejection fraction, excess glycogen accumulation, fibrosis, Z-disk disarray, swollen/fragmented mitochondria, decreased mitochondrial function, and broad glycosylation changes including significant alterations in sarcolemmal proteins (e.g., laminin-211 subunits). AAV9-mediated PGM1 gene replacement prevented and halted DCM progression.\",\n      \"method\": \"Conditional cardiomyocyte-specific knockout mouse, echocardiography, histology, ultrastructural analysis, transcriptomics, proteomics, glycoproteomics, AAV9 gene therapy rescue\",\n      \"journal\": \"Translational research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with defined cardiac phenotype, multiple orthogonal molecular readouts (transcriptomics, proteomics, glycoproteomics), and rescue by gene therapy\",\n      \"pmids\": [\"36709920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In Pgm1 knockout C2C12 myoblasts, loss of PGM1 impairs maturation to myotubes. Dynamic flux analysis using 13C6-galactose revealed a block in the use of galactose for energy production. Knockout cells showed lower basal respiration and mitochondrial ATP production capacity, which were not restored by D-galactose supplementation, indicating a glycosylation-independent energy deficit.\",\n      \"method\": \"CRISPR/Cas9 knockout of Pgm1 in C2C12 myoblasts, 13C6-galactose tracer metabolomics, mitochondrial respiration assays (Seahorse)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — genetic KO with isotope tracer metabolomics and direct mitochondrial function measurement; multiple orthogonal methods in one study\",\n      \"pmids\": [\"37175952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DCM in PGM1-CDG can develop as a consequence of impaired binding of PGM1 to the heart-specific isoform of ZASP (LDB3), a sarcomeric Z-disk protein, independently of overall glycosylation efficiency. Thus, even when PGM1 mutations impair the ZASP-PGM1 complex, galactose supplementation cannot be expected to restore that function.\",\n      \"method\": \"Clinical molecular analysis; mechanistic inference from mutations affecting PGM1-ZASP interaction independently of glycosylation phenotype\",\n      \"journal\": \"JIMD reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic inference from patient data without direct biochemical confirmation of the interaction in this paper; single clinical case series\",\n      \"pmids\": [\"26303607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The disease-associated PGM1 variant L516P is insoluble, catalytically inactive, forms aggregates in S. cerevisiae, and is rapidly ubiquitylated and degraded by the proteasome. Both the aggregation pattern and abundance of PGM1 L516P are chaperone-dependent, indicating that destabilized disease-linked PGM1 variants are subject to protein quality control (PQC)-linked degradation.\",\n      \"method\": \"Yeast-based solubility and activity assays, ubiquitylation assays, proteasome inhibitor experiments, chaperone dependency experiments, computational saturation mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro/yeast functional assays for insolubility, ubiquitylation, and proteasomal degradation; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"38743592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Sec13 forms a protein complex with PGM1 and Ubqln1 (an ubiquitin ligase). Sec13 inhibits Ubqln1-mediated ubiquitination of PGM1, thereby stabilizing PGM1 and sustaining glycolysis (G6P production) in acute lung injury. Knockdown of Sec13 decreased PGM1 levels and reduced glycolytic output.\",\n      \"method\": \"Co-immunoprecipitation, protein complex analysis, ubiquitination assays, Sec13 and Pgm1 knockdown with metabolic readouts (lactate, G6P) in ALI mouse and cell models\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP establishing the Sec13-PGM1-Ubqln1 complex, ubiquitination assays, knockdown phenotype; single lab\",\n      \"pmids\": [\"39159700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PGM1-deficient iPSC-derived cardiomyocytes (iCMs) exhibit reduced beating frequency, impaired contractility, and prolonged contraction kinetics. Proteomic analysis revealed depletion of Z-disk components including LDB3 (ZASP). AlphaFold3 structural modeling predicted a direct PGM1-LDB3 interaction, which was confirmed by in vitro binding assay. Mitochondrial proteins were severely depleted, mitochondrial respiration was impaired, and extensive metabolic rewiring with energy depletion was demonstrated by tracer metabolomics.\",\n      \"method\": \"iPSC-derived cardiomyocytes from patient fibroblasts, multielectrode array (MEA) recordings, untargeted (glyco)proteomics, AlphaFold3 structural modeling, in vitro binding confirmation, tracer metabolomics, mitochondrial respiration assays\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived iCM model with multiple orthogonal functional and molecular readouts; PGM1-LDB3 interaction confirmed in vitro; single lab\",\n      \"pmids\": [\"41723528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PGM1 suppresses colorectal cancer cell migration and invasion, and its overexpression inhibits cell proliferation and promotes apoptosis; these effects are mediated via the PI3K/AKT signaling pathway.\",\n      \"method\": \"PGM1 knockdown and overexpression in CRC cell lines, Transwell migration/invasion assays, PI3K/AKT pathway analysis, in vivo tumor formation\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional KD/OE with pathway placement via inhibitor studies; single lab, no reconstitution or structural data\",\n      \"pmids\": [\"35614441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IRF6 inhibits PGM1 expression by decreasing the transcriptional activity of promoter 3 of PGM1, as shown by ChIP and dual-luciferase reporter assays. PGM1 overexpression reverses the inhibitory effects of IRF6 on neuroblastoma cell proliferation and glycolysis. Additionally, the E3 ligase TRIM59 mediates polyubiquitination and degradation of IRF6, thereby relieving IRF6-mediated transcriptional repression of PGM1.\",\n      \"method\": \"RNA sequencing, ChIP, dual-luciferase reporter assays, IRF6/PGM1 overexpression and knockdown, in vitro and in vivo proliferation and glycolysis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and dual-luciferase assay establishing direct transcriptional regulation of PGM1 by IRF6; epistasis confirmed by rescue experiment; single lab\",\n      \"pmids\": [\"40796729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In the erythroleukaemic K562 cell line, complete absence of PGM1 enzyme activity and immunoreactive protein is associated with very low levels of apparently full-length PGM1 mRNA, despite the presence of structurally intact PGM1 gene copies on chromosomes 1. This indicates that PGM1 deficiency in K562 is caused by abnormal regulation of transcription rather than gene deletion or gross rearrangement.\",\n      \"method\": \"Isoelectric focusing/activity staining, immunoblot with monospecific anti-PGM1 antibodies, FISH, Southern blot, RT-PCR\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal molecular methods (protein, RNA, DNA levels) ruling out structural causes and implicating transcriptional regulation; single lab\",\n      \"pmids\": [\"9177117\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PGM1 is an evolutionarily conserved α-D-phosphohexomutase that catalyzes the reversible interconversion of glucose-1-phosphate and glucose-6-phosphate via a ping-pong kinetic mechanism; its activity is essential for glycogen metabolism, glycolysis, and cytoplasmic nucleotide sugar biosynthesis for N-glycosylation, with its classical protein polymorphism arising from two point mutations (R220C and Y419H) and intragenic recombination, its substrate-binding D4 loop being a hotspot for disease-associated variants that impair ligand binding and loop dynamics, its expression regulated transcriptionally by IRF6 (repressor) and post-translationally by Sec13-Ubqln1-mediated ubiquitination and by AMPK-HDAC8 signaling under glucose deprivation, and its non-enzymatic interaction with the Z-disk protein LDB3/ZASP linking it to sarcomere integrity and mitochondrial function in cardiomyocytes independently of glycosylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PGM1 is an α-D-phosphohexomutase that catalyzes the reversible interconversion of glucose-1-phosphate and glucose-6-phosphate through a ping-pong kinetic mechanism, positioning it at a metabolic branch point that supplies both glycogen metabolism and the nucleotide-sugar pool (UDP-glucose, UDP-galactose) required for ER- and Golgi-linked glycosylation [#0, #2, #3]. Crystal structures of free enzyme and of G1P- and G6P-bound complexes define the substrate-binding architecture, and missense variants clustering in the domain-4 (D4) substrate-binding loop abolish activity by disrupting conserved ligand contacts and constraining loop mobility, making this loop a disease-variant hotspot [#3, #4]. Loss of PGM1 function causes a congenital disorder of glycosylation in which depletion of glucose-1-phosphate impairs both glycogen handling and glycan synthesis; galactose supplementation metabolically re-wires sugar flux to replenish UDP-galactose and restore glycan synthesis [#2]. Beyond its catalytic role, PGM1 is required for cardiac and muscle integrity: cardiomyocyte-specific knockout produces dilated cardiomyopathy with glycogen accumulation, Z-disk disarray, and mitochondrial dysfunction rescuable by gene replacement, and PGM1 deficiency impairs myotube maturation and mitochondrial respiration in a manner not corrected by galactose, indicating a glycosylation-independent energy and structural deficit [#6, #7, #11]. This non-enzymatic role is linked to a direct interaction with the Z-disk protein LDB3/ZASP [#11]. PGM1 abundance is controlled transcriptionally — repressed by IRF6 acting on promoter 3 [#13] — and post-translationally, with destabilized variants cleared by proteasomal protein quality control [#9] and the enzyme stabilized within a Sec13–Ubqln1 complex that restrains its ubiquitination [#10]. Under glucose deprivation, AMPK–HDAC8 signaling upregulates PGM1 to sustain glycolysis and oxidative metabolism in cancer cells [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Established the catalytic and regulatory behavior of PGM1 as a phosphohexomutase, distinguishing it kinetically from PGM2 and defining its substrate, cofactor, and inhibitor profile.\",\n      \"evidence\": \"In vitro kinetic assays on purified human erythrocyte isoenzymes\",\n      \"pmids\": [\"6240990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural basis for the kinetic mechanism\", \"Cellular and physiological role not addressed\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Resolved the molecular origin of the classical PGM1 protein polymorphism, showing it arises from two point mutations plus intragenic recombination rather than multiple independent loci.\",\n      \"evidence\": \"DNA sequencing of the entire coding region in individuals of known protein phenotype\",\n      \"pmids\": [\"7902568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of the polymorphic residues not characterized\", \"No disease association established for the common alleles\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showed that PGM1 deficiency can arise from transcriptional dysregulation rather than gene loss, implicating regulation of expression as a determinant of enzyme availability.\",\n      \"evidence\": \"Activity staining, immunoblot, FISH, Southern blot, and RT-PCR in K562 erythroleukemic cells\",\n      \"pmids\": [\"9177117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific transcriptional regulators not identified\", \"Mechanism of mRNA suppression unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Proposed a glycosylation-independent route to PGM1-CDG cardiomyopathy via impaired binding to the Z-disk protein ZASP/LDB3, separating structural from metabolic disease mechanisms.\",\n      \"evidence\": \"Clinical molecular analysis with mechanistic inference from patient mutations\",\n      \"pmids\": [\"26303607\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct biochemical confirmation of the PGM1-ZASP interaction in this study\", \"Single clinical case series\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the D4 substrate-binding loop as a structural hotspot where disease variants abolish activity through combined loss of ligand contacts and reduced loop dynamics, linking genotype to enzymatic failure.\",\n      \"evidence\": \"Biochemical activity assays, crystal structures of variants, and molecular dynamics\",\n      \"pmids\": [\"30122451\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address non-catalytic functions of the protein\", \"In vivo consequences of D4 variants not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mechanistically connected PGM1 deficiency to dual impairment of glycogen metabolism and glycosylation, and explained galactose therapy as metabolic re-wiring that replenishes UDP-sugars.\",\n      \"evidence\": \"Tracer-based metabolomics and de novo glycan labeling in patient fibroblasts\",\n      \"pmids\": [\"30982613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain glycosylation-independent phenotypes\", \"Tissue-specific differences in metabolic rescue not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided atomic-resolution views of human PGM1 with substrate and product bound, defining the structural basis of substrate and product recognition.\",\n      \"evidence\": \"X-ray crystallography of apo, G1P-bound, and G6P-bound enzyme\",\n      \"pmids\": [\"32221390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic intermediate states not captured\", \"No structural information on regulatory interactions\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed PGM1 downstream of AMPK–HDAC8 signaling as a stress-induced metabolic effector supporting cancer cell survival under glucose deprivation.\",\n      \"evidence\": \"AMPK and HDAC8 perturbation, ChIP, fractionation, and metabolic flux in lung cancer cells\",\n      \"pmids\": [\"32171858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HDAC8 occupancy at the PGM1 locus versus indirect effects not fully separated\", \"Generality beyond lung cancer untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Suggested a tumor-suppressive role for PGM1 in colorectal cancer acting through PI3K/AKT signaling.\",\n      \"evidence\": \"Knockdown/overexpression, migration/invasion assays, and pathway analysis in CRC lines with in vivo tumor assays\",\n      \"pmids\": [\"35614441\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pathway placement based on inhibitor studies without reconstitution\", \"Mechanistic link between catalytic activity and PI3K/AKT unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established a causal in vivo requirement for PGM1 in cardiac integrity, demonstrating dilated cardiomyopathy on loss and rescue by gene replacement.\",\n      \"evidence\": \"Cardiomyocyte-specific conditional knockout mouse with echocardiography, ultrastructure, multi-omics, and AAV9 gene therapy\",\n      \"pmids\": [\"36709920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not separate metabolic from structural contributions to the phenotype\", \"Mechanism linking PGM1 loss to mitochondrial fragmentation unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated a glycosylation-independent energy deficit upon PGM1 loss, showing impaired galactose-fueled respiration and myotube maturation not corrected by galactose.\",\n      \"evidence\": \"CRISPR knockout in C2C12 myoblasts with 13C-galactose tracing and Seahorse respirometry\",\n      \"pmids\": [\"37175952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the mitochondrial defect not defined\", \"Does not identify the non-metabolic effector responsible\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed that destabilized disease variants are eliminated by chaperone-dependent proteasomal quality control, defining a degradation route for misfolded PGM1.\",\n      \"evidence\": \"Yeast solubility/activity, ubiquitylation, proteasome inhibition, and chaperone-dependency assays with computational mutagenesis\",\n      \"pmids\": [\"38743592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Human E3 ligases and chaperones for PGM1 not identified\", \"Conducted in a yeast heterologous system\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a Sec13–PGM1–Ubqln1 complex in which Sec13 stabilizes PGM1 by restraining its ubiquitination, linking PGM1 abundance to glycolytic output in acute lung injury.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assays, and knockdown with metabolic readouts in ALI models\",\n      \"pmids\": [\"39159700\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubqln1 ubiquitination of PGM1 not reconstituted\", \"Single lab without independent confirmation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Confirmed a direct PGM1-LDB3 interaction and tied PGM1 deficiency to contractile, Z-disk, and mitochondrial defects in patient-derived cardiomyocytes, substantiating the non-enzymatic structural role.\",\n      \"evidence\": \"Patient iPSC-derived cardiomyocytes with MEA recordings, glycoproteomics, AlphaFold3 modeling, in vitro binding, and tracer metabolomics\",\n      \"pmids\": [\"41723528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction interface and affinity not quantified\", \"Causal contribution of LDB3 binding versus metabolic deficit not dissected\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified IRF6 as a direct transcriptional repressor of PGM1 via promoter 3, with TRIM59-mediated IRF6 degradation relieving repression to drive glycolysis in neuroblastoma.\",\n      \"evidence\": \"RNA-seq, ChIP, dual-luciferase reporters, and overexpression/knockdown rescue in vitro and in vivo\",\n      \"pmids\": [\"40796729\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of IRF6-PGM1 regulation beyond neuroblastoma untested\", \"Interplay with AMPK-HDAC8 regulation unexplored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the catalytic (glycosylation/glycogen) and non-enzymatic (Z-disk/LDB3, mitochondrial) functions of PGM1 are mechanistically separated and coordinated in muscle and heart remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the PGM1-LDB3 interface at residue resolution\", \"Mechanism linking PGM1 loss to mitochondrial fragmentation undefined\", \"Unknown whether disease variants disrupt catalysis, structural binding, or both\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016853\", \"supporting_discovery_ids\": [0, 2, 3, 4]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 5, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 6]}\n    ],\n    \"complexes\": [\n      \"Sec13-PGM1-Ubqln1 complex\"\n    ],\n    \"partners\": [\n      \"LDB3\",\n      \"Sec13\",\n      \"Ubqln1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}